



EXECUTIVE SUMMARY

BioMed Ventures is the strategic investment arm of BioMed Realty. We leverage our unique and proprietary combination of BioMed Realty assets and industry relationships to create value in our core real estate business and achieve superior risk-adjusted investment returns.

BioMed Ventures creates value by:

- investing strategically into leading life-science companies and top-tier institutional life-science investment firms
- building strong, value-added relationships with institutional life-science investors, senior biotech executives, and entrepreneurs
- supporting BioMed Realty's functional teams and special opportunities within the real estate portfolio

BioMed Ventures' strategy leverages the unique and proprietary position of BioMed Realty in relation to life-science companies, principally that:

- real estate demand is a key leading indicator of company growth
- seamless real estate operations and adaptability to change enable company success
- we have privileged access to our biotech clients



Bruce Steel, CFA
Managing Director

Bruce maintains extensive relationships with leading institutional life-science investors, world-class entrepreneurs, and executives developed over fifteen years of investing and operating in the biotech sector. In addition to serving as Managing Director of BioMed Ventures, Bruce serves on the leadership team of BioMed Realty. Bruce was Chief Executive Officer and Co-Founder of Rincon Pharmaceuticals from 2005 until its acquisition in 2008; previously he was Chief Business Officer at Anaphore and Head of Corporate Development at Ambit Biosciences. Bruce received his Bachelor of Arts degree from Dartmouth College, his Masters of Business Administration degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.



Nancy Hong, PhD
Senior Associate

Nancy joined BioMed Ventures in April 2013. Previously she was a senior analyst at Forward Ventures and advised biotech and pharma companies, including the Genomics Institute of the Novartis Research Foundation, entering new areas of research. From 2003 to 2006 Nancy was a senior scientist at Phenomix where she directed a scientific group, managed pharma collaborations, and evaluated research opportunities. Nancy received a Bachelor of Science with honors in biology from the California Institute of Technology, a PhD in Molecular and Cellular Biology from the University of California at Berkeley, and subsequent training in immunology and oncology as a postdoctoral fellow of The Leukemia & Lymphoma Society with Nobel-Haureate Dr. J. Michael Bishop at the University of California, San Francisco.

About BioMed Realty

We manage one of the largest life-science real estate portfolios in the world, with over \$6 billion in assets comprising 16.3 million rentable square feet of laboratory and office facilities in the major U.S. and U.K. life-science markets. Our clients include over 100 of the world's top private and public life-science companies, and we have a continuous pipeline of rapidly growing life-science companies engaging our real estate operations. BioMed Realty is a publicly traded real estate investment trust (REIT) listed on the New York Stock Exchange under the symbol BMR.

BioMed Ventures maintains a strategic relationship with the Salk Institute for Biological Studies, a top-tier Scientific Advisory Board, and a broad network of esteemed scientists and clinicians.



BioMed Ventures' Business Advisory Committee is comprised of the following distinguished life-science professionals:

- Dan Bradbury, former CEO of Amylin Pharmaceuticals
- Jay Hagan, CBO of Orexigen; founder of Amgen Ventures
- Bob More, Senior Advisor – Venture Investments at the Gates Foundation
- Kent Griffin, President and COO of BioMed Realty

For more information please email: biomedventures@biomedrealty.com.